![](https://investorshub.advfn.com/uicon/494668.png?cb=1566808978)
Sunday, October 22, 2017 12:27:42 PM
http://www.onclive.com/web-exclusives/immunestimulator-boosts-pembrolizumab-in-melanoma-patients-with-cold-tumors
1,000 patients treated at $50,000 would be 50 million dollars. If you multiply this conservative number a few years out and a ramp up in melanoma cancer patients which is expected to explode in the next 10 years, then you really get a much higher number a few years out for this one indication.
Merck would be absolutely foolish to not simply buyout Oncosec if they are given the opportunity. Punit may actually not want to give up the company if this turns out to be too good to give away. I think next year this will turn in to a licensing and milestone situation and an expansion into other indications such as TNBC. NSCLC will be the largest cancer market that Merck will dominate with their most recent 1st line approval which leapfrogged over Bristol Myers. I could see Merck making Oncosec and offer to run a new combo trial for NSCLC with trial funding.
Positive PISCES trial results next year will lead to rapid changes at Oncosec.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM